Trial Profile

Phase II Trial of GDC-0084 in Combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paxalisib (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

11 Dec 2024 According to an Kazia Therapeutics media release, data from this study will be presented at the San Antonio Breast Cancer Symposium.
05 Nov 2024 Status changed from recruiting to active, no longer recruiting.
06 Jan 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com